Topic
Mass screening
About: Mass screening is a research topic. Over the lifetime, 34508 publications have been published within this topic receiving 1365148 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: VIA screening, in the presence of good training and sustained quality assurance, is an effective method to prevent cervical cancer in developing countries.
511 citations
••
TL;DR: 'At-risk' patients had more complications, higher mortality and longer lengths of stay than 'not at- risk' patients and these variables were significantly related to components of NRS-2002, also when adjusted for confounders.
511 citations
••
TL;DR: Proteinuria was a strong, independent predictor of ESRD in a mass screening setting in Okinawa, Japan, and therefore, asymptomatic proteinuria warrants further work-up and intervention.
507 citations
••
University of California, San Francisco1, Group Health Research Institute2, University of Iowa3, Columbia University4, State University of New York Upstate Medical University5, Harvard University6, National Institutes of Health7, Duke University8, Virginia Commonwealth University9, Yale University10, University of Alabama at Birmingham11, University of Missouri12, University of California, Los Angeles13, University of Washington14, Stanford University15, Brown University16, University of Texas at Austin17
TL;DR: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older.
Abstract: Importance Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. Objective To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. Evidence Review The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events. Conclusions and Recommendations The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).
506 citations
••
TL;DR: This chapter discusses the management of cervical cancer based on the stage of disease, including attention to palliation and quality of life issues.
506 citations